Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | MVD | P53602 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457997 | 0.90 | FDPS (0.43) | FDPSBLMTDP1BTN3A1ENPP1 | |
| SCHEMBL936042 | 0.88 | FDPS (0.60) | FDPSBLMTDP1BTN3A1 | |
| SCHEMBL5134982 | 0.85 | FDPS (0.39) | FDPSBLMTDP1BTN3A1ENPP1 | |
| Triphosphate SCHEMBL15270533 | 0.85 | FDPS (0.56) | FDPSBLMTDP1BTN3A1ENPP1 | |
| SCHEMBL13184011 | 0.82 | FDPS (0.41) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL13183948 | 0.82 | FDPS (0.41) | FDPSBLMTDP1BTN3A1 | |
| Triphosphate SCHEMBL18714 | 0.82 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL15555988 | 0.82 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL29692 | 0.80 | FDPS (0.50) | FDPSBLMTDP1BTN3A1ENPP1 | |
| SCHEMBL15239278 | 0.80 | FDPS (0.50) | FDPSBLMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117425499-A | Methods of treating myotonic muscular dystrophy type 1 using peptide-oligonucleotide conjugates | 肽世代公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117295525-A | Cell penetrating peptide conjugates and methods of use thereof | 牛津大学科技创新有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-108025017-A | MiR-19 conditioning agents and application thereof | 米拉根医疗股份有限公司 | 2018-05-11 | — | — | CN | disclosed |
| US-6828148-B2 | Compound for use in the treatment of infections, arthritis, artherosclerosis, restenosis, psoriasis, cancer and leukemia | GENE SHEARS PTY. LIMITED (AU) | 2004-12-07 | — | — | US | disclosed |
| US-20020155454-A1 | Miniribozymes active at low magnesium ion concentrations | GENE SHEARS PTY. LIMITED (AU) | 2002-10-24 | — | — | US | disclosed |
| WO-2000039146-A1 | MINIRIBOZYMES ACTIVE AT LOW MAGNESIUM ION CONCENTRATIONS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020155454-A1 | Miniribozymes active at low magnesium ion concentrations | EMG1, RNASE1, MMEL1 | FDPS 2776/4885BLM 1676/4885TDP1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.